Developing Story
Hikma v. Amarin – Skinny Label Induced Infringement (SCOTUS, 2026)
The U.S. Supreme Court heard oral arguments in Hikma v. Amarin, examining whether a generic drugmaker's marketing of its product as a 'generic version' of a branded drug—without labeling the patented use—constitutes induced infringement (IPWatchdog, April 29). The case has major implications for the skinny-label mechanism central to generic drug market entry. A ruling is expected by June 2026.
Importance: 88%Confidence: 95%Mentions: 1Updated: May 2, 2026
## Hikma v. Amarin – Skinny Label Induced Infringement (SCOTUS, 2026)
### Overview
The U.S. Supreme Court heard oral arguments in *Hikma v. Amarin*, a closely-watched pharmaceutical patent case examining whether a generic drugmaker can be liable for induced infringement of a patented use that was explicitly carved out of its label (IPWatchdog, April 29). The case arose from the Court of Appeals for the Federal Circuit (CAFC), which ruled against Hikma.
### Core Legal Questions
1. Whether a generic manufacturer calling its product a "generic version" of a branded drug—while citing public sales data for that branded drug—constitutes inducement to infringe a patented use fully excluded from the generic's label (IPWatchdog, April 29).
2. Whether a complaint states an induced infringement claim if it fails to allege any instruction or statement by the defendant specifically mentioning the patented use (IPWatchdog, April 29).
### Oral Argument Dynamics
During oral arguments, some Justices reportedly questioned why the case was even before the Court, while others voiced concern that upholding the CAFC's ruling could harm the generics industry broadly (IPWatchdog, April 29). The tension between protecting branded pharmaceutical innovation and preserving the skinny-label pathway for generics was central to the argument.
### Strategic Importance
- **Skinny labeling** is a core mechanism by which generic manufacturers enter markets while avoiding infringement of method-of-use patents. A ruling adverse to Hikma could significantly chill generic market entry.
- The case implicates the pleading standards for induced infringement—potentially raising the bar for branded drug companies to challenge generics, or lowering it depending on the outcome.
- Attorneys representing generic manufacturers, branded pharma, or involved in Paragraph IV litigation should monitor this case closely.
### Parties
- **Hikma Pharmaceuticals**: Generic manufacturer and petitioner.
- **Amarin Pharma**: Branded drug company and respondent; markets Vascepa (icosapentaenoic acid) for cardiovascular risk reduction.
### Prior History
The CAFC ruled in Amarin's favor, finding that Hikma's marketing communications could constitute inducement even absent explicit label instructions regarding the patented use. Hikma petitioned the Supreme Court, which granted certiorari.
### Connections
- Existing page: *The Enforcement Asymmetry: Patent Holders & IP Rights Gaining Structural Advantage*
- Existing page: *IPR Institution Rate Decline – PTAB (2024–2026)*
- Existing page: *CAFC – Constellation Designs v. LG Electronics (Patent Eligibility, 2026)*
### What to Watch
- SCOTUS ruling expected by end of June 2026 term.
- Potential for Congress to respond legislatively if ruling restricts generic market access.
- Impact on pending ANDA litigation nationwide.